Effects of NO‐Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 5, 2015-11 ,pp. : 306-315

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients

By Di Biagio Antonio  

Journal of Infection and Chemotherapy, Vol. 18, Iss. 4, 2012-08 ,pp. : 587-590

Springer Publishing Company

Access to resources Recommend Favorite

Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM‐SVR study

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 1, 2015-01 ,pp. : 79-89

John Wiley & Sons Inc

Access to resources Recommend Favorite

Serum concentrations of protease inhibitors as predictors of HIV-related clinical events in patients on antiretroviral therapy

By Ormaasen Vidar   Sandvik Leiv   Rudberg Nina   Bruun Johan  

Scandinavian Journal of Infectious Diseases, Vol. 38, Iss. 8, 2006-08 ,pp. : 650-653

Informa Healthcare

Access to resources Recommend Favorite

New HIV protease inhibitors for drug-resistant viruses

By Rusconi Stefano   Viganòò Ottavia  

Therapy, Vol. 3, Iss. 1, 2006-01 ,pp. : 79-88

Future Medicine

Access to resources Recommend Favorite